Press Release
View printer-friendly version
Materialise Reports First Quarter 2018 Results
LEUVEN,
Highlights – First Quarter 2018
- Total revenue increased 37.5% from the first quarter of 2017 to 43,899 kEUR, driven by strong performances in our Materialise Medical segment and in our recently acquired ACTech business within our Materialise Manufacturing segment.
- Total deferred revenue from annual software sales and maintenance contracts increased by 2,116 kEUR to 20,839 kEUR from 18,723 kEUR at the end of 2017.
- Adjusted EBITDA increased 85.7% from 2,813 kEUR for the first quarter of 2017 to 5,224 kEUR.
-
Net result was (183) kEUR, or
0.00 EUR per diluted share, compared to (816) kEUR, or(0.02) EUR per diluted share, over the same period last year.
Executive Chairman
ACTech
On
First Quarter 2018 Results
Total revenue for the first quarter of 2018 increased 37.5% (2.4% excluding ACTech) to 43,899 kEUR (32,702 kEUR excluding ACTech) compared to 31,921 kEUR for the first quarter of 2017. Total deferred revenue from annual software sales and maintenance contracts amounted to 20,839 kEUR at the end of the first quarter of 2018 compared to 18,723 kEUR at the end of 2017. Adjusted EBITDA increased to 5,224 kEUR from 2,813 kEUR primarily as a result of the contribution by ACTech. Excluding ACTech, Adjusted EBITDA decreased to 2,383 kEUR. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) in the first quarter was 11.9% (7.3% excluding ACTech) compared to 8.8% in the first quarter of 2017.
Revenue from our Materialise Software segment decreased 2.9% to 8,326 kEUR for the first quarter of 2018 from 8,575 kEUR for the same quarter last year. Including deferred revenues from software sales and maintenance of 1,807 kEUR, the segment’s sales increased 7.5% compared to the prior-year period, reflecting a 26.4% increase of recurrent sales from annual and renewed licenses and maintenance fees. Segment EBITDA decreased to 2,324 kEUR from 2,993 kEUR while the segment EBITDA margin was 27.9% compared to 34.9% in the prior-year period.
Revenue from our Materialise Medical segment increased 20.3% to 11,946 kEUR for the first quarter of 2018 compared to 9,932 kEUR for the same period in 2017. Compared to the same quarter in 2017, revenue from our medical software grew 18.1%, and revenue from medical devices and services grew 21.5%. Segment EBITDA was 2,060 kEUR compared to 314 kEUR while the segment EBITDA margin increased to 17.2% from 3.2% in the first quarter of 2017.
Revenue from our Materialise Manufacturing segment increased 76.3% to 23,632 kEUR for the first quarter of 2018 from 13,407 kEUR for the first quarter of 2017. Segment EBITDA increased to 3,133 kEUR from 1,322 kEUR while the segment EBITDA margin increased to 13.3% from 9.9% for the same quarter in 2017. ACTech contributed revenue of 11,202 kEUR and segment EBITDA of 2,841 kEUR, with a segment EBITDA margin of 25.4%. Excluding ACTech, revenue decreased 7.3% to 12,430 kEUR and segment EBITDA decreased to 292 kEUR.
Gross profit was 23,955 kEUR, or 54.6% of total revenue, for the first quarter of 2018. Excluding ACTech, gross profit was 19,938 kEUR, or 61.0% of total revenue, compared to 18,477 kEUR, or 57.9% of total revenue, for the first quarter of 2017.
Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 19.4% to 23,374 kEUR for the first quarter of 2018 from 19,579 kEUR for the first quarter of 2017. Excluding ACTech, operating expenses increased, in the aggregate, 9.6% to 21,456 kEUR. Excluding ACTech, R&D expenses increased from 4,592 kEUR to 5,610 kEUR while S&M expenses increased from 9,608 kEUR to 9,844 kEUR and G&A expenses increased from 5,379 kEUR to 6,002 kEUR.
Net other operating income decreased by 469 kEUR to 549 kEUR compared to 1,018 kEUR for the first quarter of 2017. Excluding ACTech, net other operating income decreased by 172 kEUR. Net other operating income consists primarily of withholding tax exemptions for qualifying researchers, development grants, partial funding of R&D projects, currency exchange results on purchase and sales transactions, and the depreciation of intangible assets from business combinations.
Operating result increased to 1,130 kEUR from (84) kEUR for the same period prior year, primarily as a result of the contribution by ACTech. Excluding ACTech, operating result amounted to (672) kEUR. The decrease in the operating result (excluding ACTech) was the result of the 9.6% increase in operating expenses, which was offset in part by the 7.9% increase in gross profit. The operating result was also negatively affected by depreciation cost, which increased from 2,568 kEUR to 4,006 kEUR (or to 2,968 kEUR excluding ACTech).
Net financial result was (710) kEUR compared to (142) kEUR for the prior-year period. The financial result included (167) kEUR net financial expenses related to ACTech. Excluding ACTech, the variances primarily reflected increases in the interest expense on the company’s financial debt and variances in the currency exchange rates, primarily on the portion of the company’s IPO proceeds held in U.S. dollars versus the euro. The share in loss of joint venture decreased to (103) kEUR from (389) kEUR for the same period last year.
The first quarter of 2018 contained income tax expense of 500 kEUR, of which 416 kEUR was related to ACTech, compared to 201 kEUR in the first quarter of 2017.
As a result of the above, net loss for the first quarter of 2018 was (183) kEUR (or (1,402) kEUR excluding ACTech), compared to net loss of (816) KEUR for the same period in 2017. Total comprehensive loss for the first quarter of 2018, which includes exchange differences on translation of foreign operations, was (278) kEUR compared to a loss of (694) kEUR for the same period in 2017.
At
2018 Guidance
As detailed in the company’s year-end fiscal 2017 earnings announcement, in fiscal 2018, management expects to report consolidated revenue between 180,000 - 185,000 kEUR and Adjusted EBITDA between 22,000 – 25,000 kEUR. Management also expects the amount of deferred revenue the company generates from annual licenses and maintenance in 2018 to increase by an amount between 2,000 - 4,000 kEUR as compared to 2017.
Non-IFRS Measure
Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding non-cash stock-based compensation expenses and acquisition-related expenses of business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the company's day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company's business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company's ability to grow or as a valuation measurement. The company's calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company's presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.
Exchange Rate
This press release contains translations of certain euro amounts into
U.S. dollars at specified rates solely for the convenience of readers.
Unless otherwise noted, all translations from euros to U.S. dollars in
this press release were made at a rate of
Conference Call and Webcast
Materialise will hold a conference call and simultaneous webcast to
discuss its financial results for the first quarter of 2018 on the same
day,
To access the conference call, please dial 844-469-2530 (U.S.) or 765-507-2679 (international), passcode #7784338. The conference call will also be broadcast live over the Internet with an accompanying slide presentation, which can be accessed on the company’s website at http://investors.materialise.com.
A webcast of the conference call will be archived on the company's website for one year.
About Materialise
Materialise incorporates more than 25 years of 3D printing experience
into a range of software solutions and 3D printing services, which
Materialise seeks to form the backbone of the 3D printing industry.
Materialise’s open and flexible solutions enable players in a wide
variety of industries, including healthcare, automotive, aerospace, art
and design, and consumer goods, to build innovative 3D printing
applications that aim to make the world a better and healthier place.
Headquartered in
Cautionary Statement on Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended,
regarding, among other things, our intentions, beliefs, assumptions,
projections, outlook, analyses or current expectations, plans,
objectives, strategies and prospects, both financial and business,
including statements concerning, among other things, current estimates
of fiscal 2018 revenues, deferred revenue from annual licenses and
maintenance and Adjusted EBITDA, the benefits of the ACTech acquisition,
results of operations, cash needs, capital expenditures, expenses,
financial condition, liquidity, prospects, growth and strategies
(including our strategic priorities for 2018), and the trends and
competition that may affect the markets, industry or us. Such statements
are subject to known and unknown uncertainties and risks. When used in
this press release, the words “estimate,” “expect,” “anticipate,”
“project,” “plan,” “intend,” “believe,” “forecast,” “will,” “may,”
“could,” “might,” “aim,” “should,” and variations of such words or
similar expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon the expectations of
management under current assumptions at the time of this press release.
These expectations, beliefs and projections are expressed in good faith
and the company believes there is a reasonable basis for them. However,
the company cannot offer any assurance that our expectations, beliefs
and projections will actually be achieved. By their nature,
forward-looking statements involve risks and uncertainties because they
relate to events, competitive dynamics and industry change, and depend
on economic circumstances that may or may not occur in the future or may
occur on longer or shorter timelines than anticipated. We caution you
that forward-looking statements are not guarantees of future performance
and involve known and unknown risks, uncertainties and other factors
that are in some cases beyond our control. All of the forward-looking
statements are subject to risks and uncertainties that may cause the
company's actual results to differ materially from our expectations,
including risk factors described in the company's annual report on Form
20-F filed with the
The company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, unless it has obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
Consolidated income statement (Unaudited) |
||||||||||||||||||||||||||||
For the three months ended |
For the three |
|||||||||||||||||||||||||||
In 000 | 2018 | 2018 | 2017 | 2018 | 2017 | |||||||||||||||||||||||
U.S.$ | € | € | € | € | ||||||||||||||||||||||||
Revenue | 54,088 | 43,899 | 31,921 | 43,899 | 31,921 | |||||||||||||||||||||||
Cost of sales | (24,573) | (19,944) | (13,444) | (19,944) | (13,444) | |||||||||||||||||||||||
Gross profit | 29,515 | 23,955 | 18,477 | 23,955 | 18,477 | |||||||||||||||||||||||
Gross profit as % of revenue | 54.6% | 54.6% | 57.9% | 54.6% | 57.9% | |||||||||||||||||||||||
Research and development expenses | (6,918) | (5,615) | (4,592) | (5,615) | (4,592) | |||||||||||||||||||||||
Sales and marketing expenses | (13,059) | (10,599) | (9,608) | (10,599) | (9,608) | |||||||||||||||||||||||
General and administrative expenses | (8,822) | (7,160) | (5,379) | (7,160) | (5,379) | |||||||||||||||||||||||
Net other operating income (expenses) | 676 | 549 | 1,018 | 549 | 1,018 | |||||||||||||||||||||||
Operating (loss) profit | 1,392 | 1,130 | (84) | 1,130 | (84) | |||||||||||||||||||||||
Financial expenses | (1,910) | (1,550) | (919) | (1,550) | (919) | |||||||||||||||||||||||
Financial income | 1,036 | 840 | 777 | 840 | 777 | |||||||||||||||||||||||
Share in loss of joint venture | (127) | (103) | (389) | (103) | (389) | |||||||||||||||||||||||
(Loss) profit before taxes | 391 | 317 | (615) | 317 | (615) | |||||||||||||||||||||||
Income taxes | (616) | (500) | (201) | (500) | (201) | |||||||||||||||||||||||
Net (loss) profit for the period | (225) | (183) | (816) | (183) | (816) | |||||||||||||||||||||||
Net (loss) profit attributable to: | ||||||||||||||||||||||||||||
The owners of the parent | (225) | (183) | (816) | (183) | (816) | |||||||||||||||||||||||
Non-controlling interest | − | − | − | − | − | |||||||||||||||||||||||
Earnings per share attributable to owners of the parent | ||||||||||||||||||||||||||||
Basic | 0.00 | 0.00 | (0.02) | 0.00 | (0.02) | |||||||||||||||||||||||
Diluted | 0.00 | 0.00 | (0.02) | 0.00 | (0.02) | |||||||||||||||||||||||
Weighted average basic shares outstanding | 47,428 | 47,428 | 47,325 | 47,428 | 47,325 | |||||||||||||||||||||||
Weighted average diluted shares outstanding | 47,428 | 47,428 | 47,325 | 47,428 | 47,325 |
Consolidated statements of comprehensive income (Unaudited) |
||||||||||||||||||||
For the three months ended |
For the three |
|||||||||||||||||||
In 000 | 2018 | 2018 | 2017 | 2018 | 2017 | |||||||||||||||
U.S.$ | € | € | € | € | ||||||||||||||||
Net profit (loss) for the period | (225) | (183) | (816) | (183) | (816) | |||||||||||||||
Other comprehensive income | ||||||||||||||||||||
Exchange difference on translation of foreign operations | (117) | (95) | 122 | (95) | 122 | |||||||||||||||
Other comprehensive income (loss), net of taxes | (117) | (95) | 122 | (95) | 122 | |||||||||||||||
Total comprehensive income (loss) for the year, net of taxes | (342) | (278) | (694) | (278) | (694) | |||||||||||||||
Total comprehensive income (loss) attributable to: | ||||||||||||||||||||
The owners of the parent | (342) | (278) | (694) | (278) | (694) | |||||||||||||||
Non-controlling interest | − | − | − | − | − |
Consolidated statement of financial position (Unaudited) |
||||||
As of March |
As of December |
|||||
In 000 | 2018 | 2017 | ||||
€ | € | |||||
Assets | ||||||
Non-current assets |
||||||
Goodwill | 18,504 | 18,447 | ||||
Intangible assets | 27,770 | 28,646 | ||||
Property, plant & equipment | 88,339 | 86,881 | ||||
Investments in joint ventures | 31 | |||||
Deferred tax assets | 332 | 304 | ||||
Other non-current assets | 3,022 | 3,667 | ||||
Total non-current assets | 138,967 | 137,976 | ||||
Current assets |
||||||
Inventories | 10,426 | 11,594 | ||||
Trade receivables | 39,635 | 35,582 | ||||
Other current assets | 9,927 | 9,212 | ||||
Cash and cash equivalents | 44,697 | 43,175 | ||||
Total current assets | 104,685 | 99,563 | ||||
Total assets | 243,652 | 237,539 | ||||
As of March |
As of December |
|||
In 000 | 2018 | 2017 | ||
€ | € | |||
Equity and liabilities | ||||
Equity | ||||
Share capital | 2,735 | 2,729 | ||
Share premium | 80,209 | 79,839 | ||
Consolidated reserves | (4,603) | (3,250) | ||
Other comprehensive income | (1,898) | (1,803) | ||
Equity attributable to the owners of the parent | 76,443 | 77,515 | ||
Non-controlling interest | − | − | ||
Total equity | 76,443 | 77,515 | ||
Non-current liabilities |
||||
Loans & borrowings | 82,598 | 81,788 | ||
Deferred tax liabilities | 6,711 | 7,006 | ||
Deferred income | 7,051 | 5,040 | ||
Other non-current liabilities | 1,833 | 1,904 | ||
Total non-current liabilities | 98,193 | 95,738 | ||
Current liabilities |
||||
Loans & borrowings | 12,197 | 12,769 | ||
Trade payables | 17,631 | 15,670 | ||
Tax payables | 3,574 | 3,560 | ||
Deferred income | 22,060 | 18,791 | ||
Other current liabilities | 12,554 | 13,496 | ||
Total current liabilities |
68,016 | 64,286 | ||
Total equity and liabilities | 242,652 | 237,539 |
Consolidated statement of cash flows (Unaudited) |
||||||
For the three months ended March 31, | ||||||
in 000 | 2018 | 2017 | ||||
€ | € | |||||
Operating activities | ||||||
Net (loss) profit for the period | (183) | (816) | ||||
Non-cash and operational adjustments | ||||||
Depreciation of property, plant & equipment | 2,700 | 1,945 | ||||
Amortization of intangible assets | 1,305 | 623 | ||||
Share-based payment expense | 89 | 329 | ||||
Loss (gain) on disposal of property, plant & equipment | − | (2) | ||||
Movement in provisions | (16) | 4 | ||||
Movement reserve for bad debt | 84 | 122 | ||||
Financial income | (667) | (136) | ||||
Financial expense | 1,067 | 359 | ||||
Impact of foreign currencies | 310 | (81) | ||||
Share in loss of a joint venture (equity method) | 103 | 389 | ||||
(Deferred) Income taxes | 501 | 204 | ||||
Other | (88) | (72) | ||||
Working capital adjustment & income tax paid | ||||||
Increase in trade receivables and other receivables | (4,372) | (3,452) | ||||
Decrease (increase) in inventories | 1,147 | (406) | ||||
Increase in trade payables and other payables | 5,027 | 2,729 | ||||
Income tax paid | (807) | (136) | ||||
Net cash flow from operating activities | 6,200 | 1,603 |
For the three months ended March 31, | ||||||||
in 000 | 2018 | 2017 | ||||||
€ | € | |||||||
Investing activities | ||||||||
Purchase of property, plant & equipment | (4,275) | (7,507) | ||||||
Purchase of intangible assets | (324) | (327) | ||||||
Proceeds from the sale of property, plant & equipment & intangible assets (net) | 20 | 70 | ||||||
Acquisition of subsidiary | − | − | ||||||
Investments in joint-ventures | − | (500) | ||||||
Interest received | 14 | 108 | ||||||
Net cash flow used in investing activities | (4,565) | (8,156) | ||||||
Financing activities | ||||||||
Proceeds from loans & borrowings | 12,413 | 7,710 | ||||||
Repayment of loans & borrowings | (11,388) | (756) | ||||||
Repayment of finance leases | (760) | (728) | ||||||
Capital increase | 207 | |||||||
Interest paid | (404) | (152) | ||||||
Other financial income (expense) | 5 | (166) | ||||||
Net cash flow from (used in) financing activities | 73 | 5,908 | ||||||
Net increase of cash & cash equivalents | 1,708 | (645) | ||||||
Cash & cash equivalents at beginning of the year | 43,175 | 55,912 | ||||||
Exchange rate differences on cash & cash equivalents | (186) | (196) | ||||||
Cash & cash equivalents at end of the year | 44,697 | 55,071 |
Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited) |
||||||||||
For the three months |
For the three months |
|||||||||
In 000 | 2018 | 2017 | 2018 | 2017 | ||||||
€ | € | € | € | |||||||
Net profit (loss) for the period | (183) | (816) | (183) | (816) | ||||||
Income taxes | 500 | 201 | 500 | 201 | ||||||
Financial expenses | 1,550 | 919 | 1,550 | 919 | ||||||
Financial income | (840) | (777) | (840) | (777) | ||||||
Share in loss of joint venture | 103 | 389 | 103 | 389 | ||||||
Depreciation and amortization | 4,006 | 2,568 | 4,006 | 2,568 | ||||||
EBITDA | 5,136 | 2,484 | 5,136 | 2,484 | ||||||
Non-cash stock-based compensation expense (1) | 88 | 329 | 88 | 329 | ||||||
Acquisition-related expenses business combinations | − | − | − | − | ||||||
ADJUSTED EBITDA | 5,224 | 2,813 | 5,224 | 2,813 |
(1) | Non-cash stock-based compensation expenses represent the cost of equity-settled and cash-settled share-based payments to employees. |
Segment P&L (Unaudited) |
||||||||||||||||||
In 000 |
Materialise |
Materialise |
Materialise |
Total |
Unallocated |
Consolidated |
||||||||||||
€ | € | € | € | € | € | |||||||||||||
For the three months ended March 31, 2018 | ||||||||||||||||||
Revenues | 8,326 | 11,946 | 23,632 | 43,904 | (5) | 43,899 | ||||||||||||
Segment EBITDA | 2,324 | 2,060 | 3,133 | 7,517 | (2,381) | 5,136 | ||||||||||||
Segment EBITDA % |
27.9% | 17.2% | 13.3% | 17.1% | 11.7% | |||||||||||||
For the three months ended March 31, 2017 | ||||||||||||||||||
Revenues | 8,575 | 9,932 | 13,407 | 31,914 | 8 | 31,922 | ||||||||||||
Segment EBITDA | 2,993 | 314 | 1,322 | 4,629 | (2,145) | 2,484 | ||||||||||||
Segment EBITDA % |
34.9% | 3.2% | 9.9% | 14.5% | 7.8% |
(1) | Unallocated Revenues consist of occasional one-off sales by our core competencies not allocated to any of our segments. Unallocated Segment EBITDA consists of corporate research and development, corporate headquarter costs and other operating income (expense). |
Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited) |
||||||||||
For the three months |
For the three months |
|||||||||
In 000 | 2018 | 2017 | 2018 | 2017 | ||||||
€ | € | € | € | |||||||
Net profit (loss) for the period | (183) | (816) | (183) | (816) | ||||||
Income taxes | 500 | 201 | 500 | 201 | ||||||
Financial cost | 1,550 | 919 | 1,550 | 919 | ||||||
Financial income | (840) | (777) | (840) | (777) | ||||||
Share in loss of joint venture | 103 | 389 | 103 | 389 | ||||||
Operating profit | 1,130 | (84) | 1,130 | (84) | ||||||
Depreciation and amortization | 4,006 | 2,568 | 4,006 | 2,568 | ||||||
Corporate research and development | 490 | 509 | 490 | 509 | ||||||
Corporate headquarter costs | 2,263 | 2,073 | 2,263 | 2,073 | ||||||
Other operating income (expense) | (372) | (437) | (372) | (437) | ||||||
Segment EBITDA | 7,517 | 4,629 | 7,517 | 4,629 | ||||||
View source version on businesswire.com: https://www.businesswire.com/news/home/20180504005038/en/
Source:
Investors:
LHA
Harriet Fried/Jody Burfening
212-838-3777
hfried@lhai.com